[Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors].

Rhabdomyolyse unter Cerivastatin-Monotherapie. Konsequenzen für die Therapie mit HMG-CoA-Reduktase-Hemmern?

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0400773 Publication Model: Print Cited Medium: Print ISSN: 0028-2804 (Print) Linking ISSN: 00282804 NLM ISO Abbreviation: Nervenarzt Subsets: MEDLINE

Original Publication: Berlin : Springer Verlag

Anticholesteremic Agents/*adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects ; Hypercholesterolemia/*drug therapy ; Pyridines/*adverse effects ; Rhabdomyolysis/*chemically induced ; Ubiquinone/*analogs & derivatives; Acute Disease ; Anticholesteremic Agents/pharmacokinetics ; Anticholesteremic Agents/therapeutic use ; Aryl Hydrocarbon Hydroxylases/physiology ; Biopsy ; Coenzymes ; Comorbidity ; Creatine Kinase/blood ; Cytochrome P-450 CYP2C8 ; Cytochrome P-450 CYP3A ; Cytochrome P-450 Enzyme System/physiology ; Diagnosis, Differential ; Drug Interactions ; Electromyography/drug effects ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypercholesterolemia/enzymology ; Liver Cirrhosis, Alcoholic/diagnosis ; Liver Cirrhosis, Alcoholic/enzymology ; Liver Function Tests ; Middle Aged ; Muscle, Skeletal/drug effects ; Muscle, Skeletal/pathology ; Neurologic Examination/drug effects ; Pancreatic Diseases/diagnosis ; Pancreatic Diseases/enzymology ; Pyridines/pharmacokinetics ; Pyridines/therapeutic use ; Rhabdomyolysis/diagnosis ; Stomach Neoplasms/diagnosis ; Stomach Neoplasms/enzymology ; Ubiquinone/physiology

Cerivastatine was administered as a reversible HMG-CoA reductase inhibitor (statine) to treat hypercholesterolemia until its withdrawal from the market following 52 reports of death due to drug-related rhabdomyolysis and acute renal failure. In most cases, cerivastatine was applied in combination with drugs which influenced the liver metabolism of cerivastatine via cytochromeoxidase P 450 isoenzymes. We report a well-documented case of acute rhabdomyolysis following cerivastatine monotherapy. The diagnosis was confirmed additionally by muscle biopsy.Finally,we give an overview of the current knowledge concerning therapy with HMG-CoA reductase inhibitors,1 year after the withdrawal of cerivastatine from the market.

0 (Anticholesteremic Agents)
0 (Coenzymes)
0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
0 (Pyridines)
1339-63-5 (Ubiquinone)
9035-51-2 (Cytochrome P-450 Enzyme System)
AM91H2KS67 (cerivastatin)
EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
EC 1.14.14.1 (CYP2C8 protein, human)
EC 1.14.14.1 (CYP3A protein, human)
EC 1.14.14.1 (Cytochrome P-450 CYP2C8)
EC 1.14.14.1 (Cytochrome P-450 CYP3A)
EC 2.7.3.2 (Creatine Kinase)
EJ27X76M46 (coenzyme Q10)

Date Created: 20030222 Date Completed: 20030805 Latest Revision: 20141120

20231215

10.1007/s00115-002-1441-x

12596018